Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to exa...
Main Authors: | Annika Kasprzak, Jennifer Kaivers, Kathrin Nachtkamp, Rainer Haas, Guido Kobbe, Norbert Gattermann, Ulrich Germing |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | International Journal of Environmental Research and Public Health |
Subjects: | |
Online Access: | https://www.mdpi.com/1660-4601/18/14/7629 |
Similar Items
-
Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
by: Gattermann, N., et al.
Published: (2022) -
Myelodysplastic syndromes (MDS): prognostic factors and scoring systems
by: Elizabeth Xisto Souto, et al. -
Myelodysplastic syndrome: classification and prognostic systems
by: Rosangela Invernizzi, et al.
Published: (2011-12-01) -
Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome
by: Nikolai Tcvetkov, et al.
Published: (2020-01-01) -
The Genetics of Myelodysplastic Syndromes: Clinical Relevance
by: Chiara Chiereghin, et al.
Published: (2021-07-01)